The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for Sanofi.

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

The candidate has demonstrated dupilumab-like activity and very good ... In July 2024, partner Sanofi SNY informed Kymera about its intention to rapidly expand the ongoing mid-stage studies ...

The 20,000-year-old fossilized bones of "Ushikawa Man," thought to be some of Japan's most ancient human fossils, are not what scientists believed they were, new research finds. Instead ...

Welcome to the Sanofi Presentation at the 43rd J.P. Morgan ... is pretty interesting from our perspective and orthogonal to dupilumab. But also, subsequently we've worked out exactly why former ...

When Homo sapiens appeared some 300,000 years ago, at least six other human species already shared the planet. Here, in the studio of paleoartist John Gurche, are model representations of those ...

Here's a look at some of the absolute best. Q: Can you talk about Human Within's early days? How did the idea take shape initially and what inspired you? Winkler: Our goal was to tell a unique ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Snapshot of the implementation used to generate figures and numerical results from the paper "Sharp Bounds for Continuous-Valued Treatment Effects with Unobserved ...